Previous 10 | Next 10 |
Hepion's leading candidate CRV431 may have the best anti-fibrotic effect among the numerous NASH candidates. CRV431's analogs have been widely studied in various clinical trials, and were proven to be well-tolerated. Hepion's management has extensive experience with cyclophilin in...
Lupkynis is the first FDA-approved oral therapy for lupus nephritis. Approved label supports patented dosing protocol, which will last until 2037. 65k annual revenue is expected per lupus nephritis patient. ~10% lupus nephritis market penetration in five years will give Aurini...
In the following, I review the recent FDA approval and label for LUPKYNIS and tease out some of the bullish implications. I then consider more factors in the comparison to competitor drug Benlysta. Finally, I build and justify a DCF model which yields a new price target of $64.25 ...
After nearly two and a half decades, Aurinia Pharmaceuticals' immunosuppressant voclosporin finally garnered FDA approval last week. After flunking a Phase 2/3 dry eye syndrome trial in October 2020, voclosporin for lupus nephritis (LN) is the only meaningful asset/indication for the ...
Kezar is a founder-driven company with deep expertise in proteasome and drug development, and they have a track record of approved medicines. The company's lead asset, KZR-616, is a first-in-class inhibitor of the immunoproteasome with the potential to become a pipeline-in-a-pill for ...
Shares of Aurinia Pharmaceuticals (NASDAQ: AUPH) recently jumped thanks to excitement about the company's new lupus treatment. The Food and Drug Administration recently made voclosporin (brand name Lupkynis) the company's first commercial-stage product. Analysts who follow Aurin...
Shares of Aurinia Pharmaceuticals (NASDAQ: AUPH) , a mid-cap biotech company, closed trading Monday up by a healthy 26%. The stock raced higher in response to the FDA's approval of the company's oral lupus nephritis drug, Lupkynis (aka voclosporin). Lupkynis is indicated for pat...
FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “ Aurinia Pharmaceuticals Receives FDA Approval for LUPKYNIS” Aurinia Pharmaceuticals (NASDAQ: AUPH) soared over 37% in premarket trading after the FD...
Aurinia Pharmaceuticals (AUPH) has surged ~24.5% in response to its late Friday announcement of FDA approval for LUPKYNIS (voclosporin) for adults with active lupus nephritis.In a conference call arranged to discuss the regulatory win, the company estimated that the average ann...
Express (EXPR) +131%.TS Innovation Acquisitions (TSIA) +82% on merger agreement with Latch Inc..Aemetis (AMTX) +60%.Spartan Acquisition Corp. II (SPRQ) +51% on entering into business combination agreement with Sunlight.VYNE Therapeutics (VYNE) +40%.GameStop (GME) +43%.Aurinia Pharma...
News, Short Squeeze, Breakout and More Instantly...
Aurinia Pharmaceuticals Inc Company Name:
AUPH Stock Symbol:
NASDAQ Market:
Aurinia Pharmaceuticals Inc Website:
Viridien ADR (CGGYD) is expected to report for Q2 2024 Civitas Resources Inc. (CIVI) is expected to report $2.9 for Q2 2024 Aptiv PLC (APTV) is expected to report $1.37 for Q2 2024 Ardelyx Inc. (ARDX) is expected to report $-0.1 for Q2 2024 Beazer Homes USA Inc. (BZH) is expected ...
Company achieved $57.2 million in total net revenue and $55.0 million in net product revenue for the second quarter of 2024, representing year-over-year growth of approximately 38% and 34% respectively Company generated approximately $15.8 million in free cash flow in the second quarter a...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the second quarter of 2024 on Thursday, August 1, 2024, before markets open. Aurinia’s management team will host a conference call/webcast at 8:30...